对Ⅱ、Ⅲ期根治术后直肠癌实施三维适形放疗联合卡培他滨化疗的临床效果观察

目的探讨三维适形放疗联合卡培他滨化疗对Ⅱ、Ⅲ期根治术后直肠癌的临床疗效。方法：选择我院收治Ⅱ、Ⅲ期直肠癌根治术治疗的患者共50例作为研究对象，随机分为观察组及对照组，每组均为25例。对照组患者术后实施三维适形放疗;观察组患者术后实施三维适形放疗联合卡培他滨化疗，对比分析2组的临床疗效。结果；（1）3年生存率：观察组患者的3年生存率为92％（23／25）；对照组为84％（21／25），组间无统计学差异（P〉0．05）。（2）3年局部复发率：观察组为5％（2／25）；对照组为2096（S／26），差异有统计学意义（P〈0．05）；（3）不良反应发生率：观察组患者的不良反应发生率显著高于对照组（P〈0．05）。结论：三维适形放疗联合卡培他滨化疗可降低Ⅱ、Ⅲ期根治术后直肠癌的复发几率，积极改善患者的预后。

Objective Study of three dimensional conformal radiotherapy combined with clinical efficacy of capecitabine chemotherapy on stage after radical resection of rectal cancerMethods：Our hospital Ⅱ and Ⅲ tectal cancer radical operation in the treatment of patients with a total of 50 cases were retrospectively analyzed in patients with basic information.For grouping patients with random distribution, observation group and control group were 25 eases,The control group of patients after the implementation of the implementation of three-dlmenional eonformaf radiotherapy; three--dimensional conformal radiotherapy combined with capecitabine chemotherapy for the patients in the observation group, compared the clinical curative effect of patients with.Results： （1）The 3 year survival rate：The observation group of patients with 3 year survival rate was 92% （23/ 25）; the control group of patients with 3 year survival rate was 84% （21/25）, although the survival rate was higher in observation group, without significant difference between groups （P〉0.05）.（2） 3 years local recurrence rate：Observe the 3 year recurrence rate were 5% （2/25）; the control group 3 years local recurrence rate of patients was 20% （8/25）, the difference was statistically aignificant （P〈0.05）;（3） the incidence of adverse reaction：The observation group of patients with adverse reaction rate was significantly higher than the control group, the difference was statistically significant （P〈 0.05）.Conclusion：The risk of recurrence of three-dimensional conformal radiotherapy combined with capecitabine chemotherapy can reduce the Ⅱ and Ⅲ phase after radical resection of rectal carcinoma, and actively improve the prognosis of patients.